A B S T R A C T Both the isolated perfused rabbit heart and kidney are capable of synthesizing prostaglandin (PG) I2. The evidence that supports this finding includes: (a) radiochemical identification of the stable end-product of PGI2, 6-keto-PGF,l, in the venous effluent after arachidonic acid administration; (b) biological identification of the labile product in the venous effluents which causes relaxation of the bovine coronary artery assay tissue and inhibition of platelet aggregation; and (c) confirmation that arachidonic acid and its endoperoxide PGH2, but not dihomo-y-linolenic acid and its endoperoxide PGH, serve as the precursor for the coronary vasodilator and the inhibitor of platelet aggregation. The rabbit heart and kidney are both capable of converting exogenous arachidonate into PGI2 but the normal perfused rabbit kidney apparently primarily converts endogenous arachidonate (e.g., generated by stimulation with bradykinin, angiotensin, ATP, or ischemia) into PGE2; while the heart converts endogenous arachidonate primarily into PGI2. Indomethacin inhibition of the cyclo-oxygenase unmasks the continuous basal synthesis of PGI2 by the heart, and of PGE2 by the kidney. Cardiac PGI2 administration causes a sharp transient reduction in coronary perfusion pressure, whereas the intracardiac injection of the PGH2 causes an increase in coronary resistance without apparent cardiac conversion to PGI1. The perfuLsed heart rapidly degrades most of the exogenous endoperoxide probably into PGE2, while exogenous PGI2 traverses the heart without being metabolized. The coronary vasoconstriction produced by PGH2 in the normal perfused rabbit heart suggests that the endoperoxide did not reach the PGI2 synthetase, whereas
INTRODUCTION
An endogenous prostaglandin (PG)'-like substance (measured by superfusion bioassay techniques) synthesized by the isolated perfused rabbit heart appeared to be the mediator of coronary vasodilation produced by several vasoactive substances. The evidence that supports this contentioni includes: (a) the conicenitration of PG-like-substance in the cardiac venous effluent was directly proportional the concenitrationi of the coronary vasodilator stimulus (e.g., bradvkinini, anigioteinsii II, or exogenous arachidonate); (b) the PG release and coronary dilation produced by the agoinists was correlated both temporally and quantitatively; and (c) abolition of cardiac PG biosvnthesis by indonmethacin abolished the decrease in coronary resistanice prodtuced by these agonists (1) (2) (3) (4) .
An arachidonate metabolite, other than PGE2 and PGF2, may be responsible for the mainitenianice of coronary resistance. Exogenous arachidonic acid (AA) (the PG precursor) decreased coronary arterial resistance in the isolated perfused rabbit heart (4). Arachidonate also directly relaxed isolated spiral strips of bovine and human coronary arteries (5) , which is in conitrast to the primary prostaglandins PGE2 or PGF.,2 which contracted isolated coronary strips (5) (6) (7) (8) . In additioni, inhibition of PG eyclooxygeniase in isolated coronary artery strips led to a rapid and sustained inerease in coronary tonie (5, 7, 8) . When the enidogeniouis phos-pholipids of the isolated rabbit heart or of isolated bovine coronary artery strips were labeled with [14C]AA (9, 10) , the primary metabolite of AA released had chemical and chromatographic properties identical with the biologically inactive 6-keto-PGF1a (10, 12) . Exogenious PGH2 also relaxed bovine coronary artery strips, but the endoperoxide itself was rapidly degraded (13) (14) (15) . A potent coronary relaxant was produced by incubating PGH2 with microsomes from bovine coronary arteries (10, 15) . The struicture of the labile intermiiediate between the PG enidoperoxides and 6-keto-PGFi,, has been chemically characterized to be 9-deoxy-6, 9a-epoxy-_5-PGFI, (termed prostacyclin or PGI2) (16) . PGI2 has been discovered to be a potent inhibitor of platelet aggregation (17) and activator of platelet adenyl cyclase activity (18, 19) . The evidence that implicates PGI2 biosynthesis as a major arachidonate metabolic pathway in the isolated rabbit heart is largely based on the appearance of the inactive metabolite 6-keto-PGF1,, in the cardiac venous effluent after stimulation (11) . A number of additional criteria must be fulfilled to establish the identification and biological role of PGI2 biosynthesis in heart. These criteria include the following: ( The satisfaction of these criteria is the subject of this report. In addition, isolated perfused rabbit kidneys were utilized as a control tissue because its presumed primiary arachidoinate metabolic pathway led to PGE., synthesis and not to PGI2.
NIETHODS
Organi perfusion. The hearts were removed from mlale New Zealanld rabbits aniesthetized with pentol)arbital and perflised xvia the aorta at 3() ml/min with Krebs-Hanseleit buffer (37°C in 95%02/5% C02). The kidneys were perfused via the renal artery at 15 ml/min. Superfusion bioassay. The venous effluent from either the perfused heart or kidney continuously bathed assay tissues hunlg in a vertical superfusion cascade (1) (2) (3) (4) . Bovine coronary artery was excised from freshly removed hearts and spiral strips were prepared (5). The bovine coronary artery strip is contracted by PGE2 (5-7) and PGH, (12) and relaxed uponl exposuire to PGH2, PGI2, or PGE, (12, 14) . 6-Keto-PGF,1 (0.1-5 ,ug) caused no detectable response on the bovine coronary strips. Direct application of arachidonic acid would relax the coronary artery strips (5), but the assay tissues were continuously treated with indomethacin (300-1,000 ng/ml) and therefore were unresponisive to exogenous or endogenous AA. The chick rectum andl occasionally the rat fundal stomach strip were employed to indicate the presence of a PGE2-likesul)stance in the venous effluent. The assay tissues were also continuously perfused with a mixture of antagonists to render the strips insensitive to catecholamines, serotoninl, acetylcholine, or histamine.
Platelet aggregationi bioassay for the presence of PGI2 in cardiac or renal vetnous effluent. Citrated human plateletrich-plasma was prepared as previously described (20) . The infusion of indomethacin and the mixture of antagonists across the assay tissues in the superfusion cascade was interrupted 5 min before the collection ofthe venous effluent for testing on platelets. Thus, these inhibitors did not interfere with the platelet assay. The venous effluent from a perfused heart or kidney was collected below the assay tissues for 3 min after organ stimulation. The pooled effluent was well mixed and a 50-,l aliquot was taken and added to 400 gl of platelet-richplasma and incubated for 2 min with stirring at 37°C in a Payton Dual Channel aggregometer. Aggregation was initiated with AA. Radiolabeling technique. The method of incorporationi of radioactive AA into the heart or kidney lipids has been described in detail elsewhere (9 seminal vesicle acetone-pentane powder and purified as previously described (22, 23) . PGI2 was chemically synithesized as previously described (24) . Authentic 6-keto-PGF10' and PGI2 were also kinidly supplied by Dr. Pike anid the Upjohn Company. Bovine artery microsomes were prepared f'rom freshly dissected vessels. The arteries wvere homogenized (Polytron, Brinkmann Instrumenits, Inc.) and centrifuiged for 10 min at 10,000 g. The suipernate was cenitrif'uiged for 60 min 840 P. Needlemiiatl, S. D. Brotnsotn, A. W17ilche, Ml. Sivakoff, and K. C. Nicolaoui aIt 100,000 g. The pellet was resusl)ended in a 50-mM phosphate l)uffer (pH 7.4) aind stored at -70°C. The 15 hvdroperoxv AA (an in vitro PGI, svnthetase inhibitor [25] ) wats svynthlesize(i enzymiuatical ly Withl soybean lipoxygenase atnid ptirifiedl as p)reviously described (26) .
RESULTS
Deterininiationi of the cardiac release ofa vlasodilator substat ce twith bioassay technlii(tes. The isolated rabbit heart was perfused with K.rebs-Hanseleit media and the venouis effluent continuously bathed a series of isolated smooth mullscle strips selected for their responsiveness to PG. Intracardiac injection of AA (5,8,11,14-eicosatetraenioic acid = C20:4) or bradykinin (BK) resulted in the appearaniee in the cardiac venious effluenit of a sulbstance which relaxed the bovine coronary artery assay strip (Fig. 1) , associated with a concentrationldepenidenit decrease in coronary perf'usion pressure (1, 4) . In contrast, initracardiac dihomo-y-linolenic acid (8,11,14-eicosatrieinoic acid=C20:3) resulted in the appearaniee of'a suibstaniee in the venious effluent which conitracted the chick recttum assav tissue (suggestive of PGE,) and conitracted the bovine coronary artery (suggestive of'PGH,). The lack of'the 5-6 double bond in dihomo-y-liioleniic acidl preeludes its coniversioni to PGI., (11) . The inftusion of inidomiiethacini inlto the perf'used rabbit heart retsulted in the simiiultanieouis contractioni of' the bovinie coronary strilp ani(l relaxationi of' the chick rectumll which were continuouslx bathed with the cardiac venouis effluenit (Fig. 1) . Siniee the cyclo-oxygenase in the assay tissues was previously inhibited by indomethacini applied directly across the assay tissues but not into the heart, the contractioni of' the bovine coronary strip produced by the intracardiac indoimiethacini reflects the disappearaniee of' the low coneenitrationi of continuously released PGI.2 from the cardiac ef'fluenit. The inlfusionl of inidomiiethaciin througlh the heart inhibits the cardiac PG biosynthesis induced by BK (not shown), and(l the fatty acids (Fig. 1) .
The intra-cardiae inijection of' the potent peptide vasoconstrictor (on isolated1 blood vessels anld on 1)lood0 pressuire) anigiotenisin II actually causedl a decrease in cardiac perfusioni pressure in the conistanit flow perf'uised heart (as did BK or tranisienit cardiac ischemliea) and(c resulted in the appearaniee in the cardiac efflutenit of' a stubstancie which relaxed the bovinie coronary artery strip ( Fig. 1 ). However, wheni ind(lomethacini was inf'used inlto the heart, initra-cardiac adminiistrationi of' angiotensin resulted in increased vascular resistance in the perfused heart and no vasoactive substance was present in the effluent (Fig. 1) . Renal PGI2 biosynthesis. For comparative purposes we studied PG biosynthesis in isolated perfused rabbit kidney. BK administration primarily induces renal PGE, (but not PGI2) biosynthesis as evidenced by bioassay (contraction of both the chick rectum and bovine coronary artery strip) (Fig. 2 and [27] ). Similarly, injection of angiotensin II or ATP through the kidney produced only PGE2 in the effluent (27) . Surprisingly, administration of exogenotus AA (but not dihomo-ylinolenate) to the perfused rabbit kidney resulted in (a) decrease in perfusion pressure (not shown), and (b) release of a substance which relaxed the bovine coronary strip which is suggestive of the PGI2 (Fig. 2) . Renal administration of indomethacin resulted in a simultaneous decrease in smooth muscle tone in the bovine coronary assay strip and the chick rectum ( Fig.  2) (Fig. 3) . Control samples were collected before hormone or fatty acid stimulation. The effluent obtained from the untreated heart did not contain anl adequate basal level of PG to alter AA induced aggregation (Fig. 3, upper left-hand tracing) . BK (500 ng but not 50 ng) injection into the perfused rabbit heart resulted in the presence in the cardiac venous effluent of a substance which inhibited platelet aggregation. Similar cardiac biosynthesis of an inhibitor of platelet aggregation was produced by AA and ischemia, but not by dihomo-,y-linolenic acid (Fig. 3, uipper panel) . Treatment of the heart with cyclo-oxygenase inhibitors (either indomethacin or aspirin) abolished the presence of the inhibitor of platelet aggregation in the cardiac effluent normally produced by BK, AA (Fig. 3) , angiotensin II, or ischemia (not shown). Thus, treatment of the perfused rabbit heart with AA (but not dihomo-y-linolenic acid), bradykinini, ischemia, or angiotensin II simultaneously resulted in (a) a decrease in cardiac perfusion pressure, (b) the release of a vasodilator substance, and (c) the release of an inhibitor of platelet aggregation. These three responses were blocked by indomethacin or aspirin treatment of the perfused heart.
In the kidney, (Fig. 2) , bradykinin and dihomo-ylinolenate caused the release of a coronary constrictor (Fig. 2) which did not inhibit platelet aggregation (Fig.  3, lower panel) (Fig. 4, upper panel) . In contrast, upon bradykinin stimulation of the perfused kidney the only detectable product was PGE2, whereas the heart produced both 6-keto-PGFi,, and PGE2 (Fig. 4, lower panels) .
Administration of dihomo-y-linolenic acid to the heart did not result in the release of either a substance which relaxed the coronary strip or which inhibited platelet aggregation. Furthermore, [14C]PGE, was the primary radioactive product obtained after intra-cardiac infusion of [14C]dihomo-y-linolenate (11) .
Thus, exogenous AA in the kidney or exogenous or endogenous AA in the heart release PGI2 (determined by bioassay using blood vessels and platelets) and the stable PGI2 metabolite, 6-keto-PGF1. (determined by extraction and radiochromatography.
Microsomal generation of PGI2. Direct application of PGH2 to assay tissue caused an immediate contraction of the rabbit thoracic aorta strip aind a slightly delayed relaxation ofthe dog (or bovine) coronary artery (Fig. 5) . In contrast, when the same amount of PGH2 was incubated (2 min, room temperature) with bovine coronary microsomes to enzymatically generate PGI2, the PGH2 activity (aorta constrictioin) disappeared and an immediate profound coronary relaxation was produced (Fig. 5) . The relaxing activity disappeared if a 15-min delay was permitted between incubation and testing. The radioactive product obtained from longterm (15-min) incubations of [14C]PGH2 with blood vessel microsomes, was a mixture of 6-keto-PGF1,, and PGE2 (Fig. 6) . Incubation of PGH, (no 5-6 double bond) with bovine coronary artery microsomes did not result in disappearance of the PGH,-induced aorta contraction nor an alteration in the contractile effect on the coronary assay tissue (Fig. 5) (11) . Additional confirmation of the synthesis of PGI2 is illustrated by the selective inhibition of 6-keto-PGFsa by preincubations of the blood vessel enzyme with 15-hydroperoxy-arachidonic acid (Fig. 6 middle panel) . PGH2 was 10% as potent as PGI2 in directly relaxing the bovine coronary artery assay tissue, whereas 6-keto-PGF1, was inactive (0.1-10 ,ug).
Exogenous administration of PGI2 and PGH2. Cardiac administration of PGI2 caused a sharp transient reduction in coronary perfusion pressure (Fig. 7) . Myocardial degradation seemed minimal since comparable bovine coronary relaxation was produced when the PGI2 was tested directly over the assay tissue or when injected into the heart (Fig. 7, Table I ). On the other hand, rapid efficient renal destruction was suggested by the 90% loss in PGI2 biological activity in one transit across the perfused rabbit kidney (Table I) .
Whereas cardiac administration of PGI2 or AA produced a reduction in coronary perfusion, PGH2 produced a small increase. Low doses of PGH2 injected as a bolus through the heart were rapidly converted to a PGE2-like substance that contracted the bovine coronary artery assay tissue (Fig. 7) . Higher doses of intracardiac endoperoxide were not completely degraded in the heart and the venous effluent contained a substance which contracted the rabbit aorta and caused a biphasic relaxation and contraction of coronary strip (Fig. 7) . The dose response curves for rabbit aorta FIGURE 5 Comparative response of the rabbit aorta and dog coronary artery to endoperoxide, (PGH2 or PGH,), or the product of the incubation (2 min at 22°C) of the endoperoxide and bovine coronary artery microsomes (BOV. COR. M:ICR.) (100,000 g pellet). Rabbit thoracic aorta strips contract in response to PGG,, PGH2, and thromboxane A, but are nonresponsive to PGI2 (14) .
contractions produced by PGH2 either applied directly or injected through the heart indicated that 86+5% (n = 4) ofthe endoperoxide was degraded in one transit across the heart.
Infusion of 15-hydroperoxy-arachidonic acid directly across the assay tissue blocked the conversion of PGH2 to PGI2 but did not affect bovine coronary artery relaxation from either directly applied or cardiacproduced PGI2 (Fig. 7) . However, intracardiac injection of high doses of PGH2 did not release a substance that relaxed the 15-hydroperoxy-arachidonic acid-treated strips (Fig. 7) . Therefore, bovine coronary relaxation after intracardiac administration of high doses of PGH2 is due to the conversion by the assay tissue of spilled PGH2 to PGI2. Any conversion of the PGH2 to PG12 by the rabbit heart, if it occurred, was below the sensitivity of the assay tissue for PGI2.
The cardiac effluent from the PGH., (up to 2 ,g) treated heart did not contain a substance that inhibited platelet aggregation. Platelet aggregation could be inhibited by as little as 0.2 ng of exogenous PGI2 (data not shown).
DISCUSSION
Both the isolated perfused rabbit heart and kidney are capable of synthesizing PGI2. The evidence presented in support of this finding include: (a) radiochemical identification of the stable end product 6-keto-PGF1,y in the venous effluents (Fig. 1) ; (b) biological identification of the labile arachidonate product in the venous effluents which causes relaxation of bovine coronary artery and which inhibits platelet aggregation (Figs.  1-4) ; and (c) confirmation that AA (20:4) but not dihomo-y-linolenic acid (C20:3) serves as the precursor for the coronar-y dilator, platelet inhibitory substance (Figs. 1, 2, and 6) . We arachidonic acid (up to 2 ,ug/ml) through the heart or kidney. Unfortunately, this agent did not appear to act on the intact organs (perhaps because of penetration problems or rapid enzymatic reduction to 15-hydroxyarachidonic acid) but the agent could block the in vitro enzymatic PGI2 formation from PGH2 by bovine aorta microsomes and bovine coronary artery (Fig. 6 ). Finally administration of PGI2 mimicked the decrease in coronary perfusion pressure produced by exogenous or endogenous AA (Fig. 7) . Although, the heart and kidney are both capable of converting exogenous arachidonate into PGI2, the normal kidney apparently primarily converts endogenous arachidonate (e.g., generated by stimulation with bradykinin, angiotensin, or ATP) into PGE2 (Fig. 4 and   [27] ). In addition, the perfused heart and kidney appear to differ in regard to the basal PG (i.e., unstimulated) present in the effluent. Thus, the changes in the muscle tone of the coronary assay strip unmasked by the organ infusion of indomethacin suggest that the heart is continuously releasing PGI2 and that the kidney is releasing PGE2 (Figs. 1 and 4) . Apparently the basal level of PGI2 released by the heart into the effluent is at too low a concentration in the effluent to inhibit platelet aggregation. The high flow rate (30 ml/min), the dilution in the aggregation experiment (ninefold), and the rapid spontaneous decay of PGI2 at pH 7.4 all tend to minimize the basal cardiac PGI2 effect on platelets.
The differential PG biosynthesis (i.e., PGI2 vs. PGE2) by the perfused kidney is perplexing. In addition, the rabbit kidney can be induced to initiate thromboxane A2 synthesis in a ureter obstruction model in response to either exogenous or endogenous arachidonate (27, 28) . Furthermore, basal and stimulated PGE2 biosynthesis is greatly exaggerated in perfused rabbit kidneys obtained from ureter obstructed animals (27) . Thus, the isolated perfused rabbit kidney can be manipulated to synthesize PGE2, PGI2 or thromboxane A2. There may be a differential distribution of enzymes for which PGH2 serves as substrate throughout the kidney. The amount of PGE2 synthesized (PGH2 -* PGE2 isomerase) in the medulla is substantially greater than that in the cortex (29, 30) . On the other hand, in the ureter obstructed rabbit kidney, total thromboxane A2 (thromboxane synthetase; PGH2 -> TXA2) production is greater in the cortex than in the medulla (28) . One possibility is that the kidney itself, (i.e., cortical or medullary tissue) does not contain PGI2 synthetase (i.e., PGH2 -*PGI2) but rather that the enzyme is localized in the renal blood vessels. Indeed, PGI2 production has been demonstrated in every blood vessel tested (5, 14, 31, 32) and there is substantial evidence that cardiac synthesis merely reflects the presence of the enzyme in the coronary blood vessels (5, 10, 12) . The resolution of the site and nature of PG biosynthesis is essential in understanding renal function since PGs are implicated in the regulation of renal resistance (33, 34) , electrolyte excretion (35) , and plasma renin synthesis and release (36 PGI2 productioni on coronary resistance is obvious. The impact on platelet aggregation of the PGI, released from the heart is less clear. The interaction of vascular PGI., production and platelet fuinction has received a great deal of attention. It has been proposed that blood vessel PGI2 synthetase "steals" the PG-endoperoxides from stimulated platelets and then the vascular enzyme manufactures PGI2 which locally' inhibits aggregation (37) . There is a lack of definitive evidence to support this hypothesis. In the current and previous investigations we have demonstrated that the isolated perfused rabbit heart rapidly converts (in one transit across the coronary vascular bed) both endogenous and exogenous AA into PGI2 (Fig. 1) 
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The values in the table are millimeters relaxation+±SEM; and n designates the number of experiments. The coronary relaxation produced by the renal venous effluent after intrarenal PGI2 injection is significantly less than that produced by applying the PGI2 directly to the coronary strip. TH It ments in the normal isolated perfused rabbit hearts serve as models of the in vivo situation, then it is difficult to visualize how the vascular enzyme could "steal" platelet endoperoxide for PGI2 production. The more likely suggestion is that the blood vessel relies on endogenous substrates (i.e., AA and PGH2) for its PGI2 biosynthesis and therefore requires local stimulation (e.g., hormonal, mechanical, or changes in oxygen tension) to activate the process.
